Ohio State Navbar

Sign In

Press & Recognition

3D Printing: Healthcare Leaders assess the impace on Device Costs and Surgical Outcomes​

HealthLeaders magazine

Print audience: 40,020

April 2016 issue

Three-dimensional printing in healthcare has received a lot of attention as a gee-whiz, futuristic technology, with photos of prosthetics for injured soldiers and children. But 3-D printing is about to get a whole lot more personal. Sophisticated imaging and modeling means that complex structures such as heart openings can be designed with such accuracy that implants work better and recovery from surgery is improved. David Dean is featured. This coverage resulted from pitching efforts by OSU Wexner Medical Center Public Affairs and Media Relations.

​​Medical Innovations: OSU Conference Highlights Breakthroughs in Regeneration​

Columbus Dispatch

Online audience: 506,980

Print audience: 138,386


The human body develops almost miraculously in the womb, quickly generating the flesh, organs and limbs that stick with people all their lives, if they're lucky. But after birth, our bodies stubbornly refuse to generate any more parts. Cut off a finger, and it won't grow back. Destroy your liver, and a fresh one won't sprout in its place. But it turns out that isn't exactly the case, said researchers during a conference on regenerative medicine and wound care being held through Saturday at Ohio State. Dr. Chandan Sen is quoted. Dr. David Dean appears in a photo. This coverage resulted from pitching efforts and a news release distributed by OSU Wexner Medical Center Public Affairs and Media Relations, available online at http://wexnermedical.osu.edu/mediaroom/pressreleaselisting/9th-annual-ohio-state-t2c-conference-features-defense-department-speakers.

Ambassador Dnyaneshwar Manohar Mulay Consul General of India in New York visits OSU

Dr. Sen-Ambassador Mulay.png
From L to R: 

Dr. Usha Menon- Centennial Professor of Nursing; Director, PhD & MS in Nursing Science Program; Director, Community Engagement, CCTS
Mr. Brent Toto- Program Director, The Center for Regenerative Medicine and Cell Based Therapies
Dr. Anil Pradhan- Professor, Department of Astronomy, Chemical Physics Program, and Biophysics Graduate Program; Director of USIEF STEM Education and Research Project
Dr. Neil Patel- President, Federation of Indian Associations
Dr. Chandan Sen- Professor, General Surgery; Professor, SBS-Molecular & Cellular Biochemistry; Associate Dean, ADM-Medicine Administration; Adjunct Professor, College of Nursing
Ambassador Dnyaneshwar Manohar Mulay - Consul General of India in New York
Dr. Rattan Lal - Professor, School of Environment and Natural Resources; Director of Carbon Management and Sequestration Center
Dr. Sultana Nahar- Research Scientist, Department of Astronomy
Dr. Amar Pandey- Chair, Federation of Indian Associations
Mr. Nirmal Sinha- Trustee, Federation of Indian Associations


Friday, May 15th
H3C– Dr. Sen


Ambassador Dnyaneshwar Manohar Mulay, Consul General of India in New York visited Ohio State University on Friday May 15th, 2015. Dr. Chandan Sen, Director of the OSU Center for Regenerative Medicine and Cell Based Therapies (CRMCBT) was invited to meet Ambassador Mulay and share information about the H3C Health Sciences Innovation Conference. The event was held January 15-17, 2015 in collaboration with the All India Institute of Medical Sciences (AIIMS). CRMCBT was a core organizer of the event and held a regenerative medicine session on day two of the three day conference. An MOU is now being executed between CRMCBT and AIIMS. OSU CRMCBT will collaborate to build the First National Facility for Regenerative Medicine in Delhi, India on the AIIMS campus. For the first project, an emphasis will be placed on Acid burn victims. The CRMCBT has obtained technology that can reverse more than 90% of the damage caused by Acid burns using Spray Technology. This Spray Technology was previously only available to the military. Ambassador Mulay was very pleased to hear about the success of the event and offered support of the consulate toward future interactions between OSU and India.


Sentinel Studies Find New Microcurrent Generating Wound Dressing Effective in Disrupting Bacterial Biofilms



TEMPE, Ariz., April 6, 2015 /PRNewswire/ -- Procellera® from Vomaris Innovations, Inc. (now available through Arthrex as JumpStart™) - the only wound dressing powered by Advanced Microcurrent Technology™, has been found to significantly disrupt bacterial biofilms, according to two new published research studies in PLoS ONE and the Journal of Wound Care1-2.

Studies conducted at The Ohio State University (OSU) Wexner Medical Center, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and its Diagnostics and Translational Research Center (DTRC) both confirmed significant anti-biofilm efficacy of Procellera Technology. Bacterial biofilms are complex networks of microorganisms bound together and covered with a slimy protective barrier. They can be found in living tissues, indwelling medical devices, and implants. Biofilm-associated bacteria are extremely resistant to antibiotics and have been implicated in wound infections, resulting in delayed healing, poor clinical outcomes and significant healthcare costs.

In the OSU study, researchers evaluated the effects of Procellera / JumpStart technology to better understand its antimicrobial properties, particularly related to the disruption of Pseudomonas aeruginosa. This bacterial species is often present in chronic wound infections and readily forms biofilm, making it extremely difficult to treat effectively with available antibiotics. 

"This work presents clear evidence that this wireless electroceutical dressing disrupts bacterial biofilm," said Chandan K Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at OSU Wexner Medical Center. "Our findings introduce the option of a new affordable technology platform to fight chronic wound infection in which bacterial biofilms are abundant." 

Several mechanisms behind the ability of this Advanced Microcurrent Technology to disrupt the formation of bacterial biofilms were identified:

 •First, the microcurrent technology aided the generation of superoxide radicals, chemical compounds that are produced by white blood cells in the body with the goal to fight infection. 

•Second, researchers discovered that the microcurrents significantly impaired the activity of glycerol-3-phosphate dehydrogenase (GPDH), an electrically sensitive enzyme that is required for bacterial respiration and metabolism. 

•Finally, the research found that the microcurrents disrupted some key antimicrobial resistance genes, silenced some key redox-sensitive, quorum sensing genes and interfered with production of bacteria signaling molecules, thus preventing the bacteria from forming the complex networks that make up biofilms.

Because bacterial biofilms are known to compromise production of antimicrobial superoxide radicals by immune cells, weakening the ability of the body to fight infection, the study's observation that Procellera initiated spontaneous generation of superoxide radicals is particularly significant. 

Research performed at DTRC and HJF studied the anti-biofilm properties of Procellera Technology against ten clinical wound pathogens in a poloxamer biofilm model customized to evaluate the bioelectric dressing. Investigators demonstrated Procellera / JumpStart's effectiveness against biofilms across multiple species of clinical wound pathogens, with up to a thousand-fold inhibition of microbial growth in several species when compared to controls. This observation is consistent with the observations reported independently from OSU.

"We are very encouraged by the implications of these results for wound care, which showed that this electroceutical dressing was effective in inhibiting growth of both mono- and multi-species biofilms, including multi-drug resistant strains," said Dr. Mina Izadjoo, principal investigator for the DTRC/HJF study.

"Bacterial biofilms can dramatically impede wound healing and penetrate deeper into a wound bed to further infect implanted devices," said Michael Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc. "Because of their resistance to treatment, biofilms present a significant challenge in today's healthcare environment. We, at Vomaris, are extremely pleased by these latest findings by two independent laboratories about this Technology's ability to inhibit and disrupt biofilms and the significant implications this has for infection control and wound healing." 


Co-authors of the Journal of Wound Care article included Hosan Kim, Ph.D. The study was supported by Vomaris.


t Vomaris Innovations

Vomaris Innovations, Inc. is an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond. Utilizing electricity to mimic the body's own physiologic electric currents, which are essential for skin repair and wound healing, Vomaris' core technology platform employs imbedded microcell batteries that generate microcurrents in the presence of a conductive medium to harness the power of electricity to suppor

t healing.


omaris' flagship product, Procellera® Antimicrobial Wound Dressing is the only wound dressing in the world powered by Advanced Microcurrent Technology. It is a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial efficacy3 and the ability to promote wound healing4, and is available exclusively through Arthrex as JumpStart Technology with Advanced Microcurrent Healing.

Procellera / JumpStart is currently used in multiple acute and chronic wound care settings, including clinical, animal and consumer health. The company's ongoing mission is to develop and deliver evidence-based, patient-focused and cost-effective solutions, backed by a commitment to quality and innovation for the improvement of lives. 

About Arthre



rthrex, Inc. is a global medical device company and leader in new product development and medical education in orthopaedics. With a corporate mission of helping surgeons treat their patients better, Arthrex has pioneered the field of arthroscopy and developed more than 8,500 innovative products and surgical procedures to advance minimally invasive orthopaedics worldwide. Arthrex remains dedicated to delivering uncompromising quality to the healthcare professionals who use its products, and ultimately, the millions of patients whose lives these products impact.

 1.Kim H, Izadjoo MJ. Antibiofilm efficacy evaluation of a bioelectric dressing in mono- and multi-species biofilms. J Wound Care 2015; 24 Suppl 2:S10-4. 

2.Banerjee J, Ghatak PD, Roy S, Khanna S, Hemann C, Deng B, et al. (2015) Silver-Zinc Redox-Coupled Electroceutical Wound Dressing Disrupts Bacterial Biofilm. PLoS ONE 10(3): e0119531. doi:10.1371/journal.pone.0119531 

3.Kim H, Makin I, Skiba J, Ho A, Housler G, Stojadinovic A, Izadjoo M. Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens.  The Open Microbiology Journal 2014; 8:15-21. 

 4.Banerjee J, Ghatak P, Roy S, Khanna S, Sequin EK, Bellman K, Dickinson BC, Suri P, Subramaniam V, Chang CJ, Sen CK.  Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLOS ONE. 2014; 9(3).



Ohio State Surgeons Implant Knee Cartilage Grown From Patient's Own Cells

Flanagan Knee Cartilage implant.jpgOhio State Surgeons Implant Knee Cartilage.jpg 
Online audience: 7,854
Print audience: 30,000
Doctors at The Ohio State University Wexner Medical Center are the first in Ohio to use a tissue implant made from a patient’s own cells to treat knee cartilage damage. Healthy cartilage is crucial to the smooth and painless mobility of most joints, and has limited capacity to repair itself after injury. “Despite the availability of procedures and treatments, patients are often left searching for new options due to incomplete recovery or limited duration of effect,” said Dr. David Flanigan, the surgeon who implanted the cartilage and associate professor of orthopaedics at Ohio State’s Wexner Medical Center. “If this implant works how we think it will, this could be a long-term, permanent solution for patients with these injuries.” To generate the implant, a surgeon first obtains a small sample of normal cartilage from a patient’s knee through a minimally invasive knee scope. The tissue sample is then treated and grown into a cartilage implant, which is returned to the injury site. In an effort to gain regulatory approval, the Neocart cartilage tissue implant is currently in an FDA-approved multi-center, randomized trial comparing the implant to the current standard-of-care for patients with articular cartilage defects of the knee. Traditionally, microfracture surgery is considered the current standard of care for most cases of severe cartilage injury in the knee. Although symptoms may improve for a period of time after surgery, microfracture doesn’t create the same healthy joint cartilage required to withstand normal forces of movement. “The hope is that embedding patients with their own cells will lead to a more durable replacement of the lost cartilage and improve patient outcomes,” Flanigan said. The Neocart implant is made by Histogenics, which is sponsoring the clinical trial. Ohio State’s Wexner Medical Center is one of approximately 30 trial sites nationwide.


U.S. News and World Report 

How 3D Printing Will Revolutionize Prosthetics 

Online audience: 2.9 million


 As technology improves, inventions that were once seen as merely science fiction are becoming reality and providing new solutions to health problems. One area of technology revolutionizing health is in the field of prosthetics, where 3-D printing allows doctors and engineers to partner to rebuild limbs faster and cheaper than ever before – especially for children. 3-D printing works by melting thin plastic filament and squeezing it through a nozzle, building up computer-generated renderings layer by layer. Using these printers, you can create almost anything – including body parts. The technology is already widely used for some medical implants, says David Dean, an associate professor in the plastic surgery department at ​The Ohio State University, who has worked extensively with 3-D printers. "Old cranial implants were hard to get right," he says. "If they didn't fit right, you could block block blood vessels or even cause seizures."​


Ohio State Researchers Lead 3D Printing Movement

May 15, 2014

Broadcast audience: 84,798

Online audience: 213,200

The biomedical research tower stands tall over the campus of The Ohio State University​, but in the basement, in a small laboratory, a 3D printer is creating a new body part. Researchers are working on the next generation of bone and tissue engineering, crafted from a computer and a 3D printer. "What it's doing is taking the shape, cutting it into slices, and printed one after another," said Dr. David Dean. The items will be infused with stem cells, placed in a bioreactor, and grown into surgical implants custom designed for a patient. Dean has been working on the research for 20 years, and he's confident it's the future. 

The S​tar Newspaper Double protection against stroke

April 27, 2014

4 27 14 Cameron Rink-Tocotrienol Vitamin E prevention of Stroke article.jpg


Making a better legs

March 27, 2013


Kevin Johnson navigated high school on crutches instead of bothering with the soreness and bleeding that came with wearing his first prosthetic leg.

But that’s changed. The right leg he gets around on today just two-stepped through Daytona Beach’s Bike Week.

When he waits on a red light, it stays on the brake of his custom Harley-Davidson without slipping to the ground. And the leg safely allows him to jump to the ground when he lands the helicopter he pilots.

It’s also proven handy for roping cattle, racing cars and operating bulldozers. (That last part is what he does for a paycheck.) Johnson, who lives southeast of Chillicothe, lost much of his leg at 14 when a combine in a field of soybeans on the family farm snagged his shoestring. That was in 1979.

More than three decades makes a big difference, as has a recent study to improve prosthetic limbs for returning troops and other amputees.

WillowWood, a prosthetic-maker in Mount Sterling, is collaborating with wound experts at Ohio State University’s Wexner Medical Center to improve prosthetics for those who’ve lost a leg above the knee.

The U.S. Department of Veterans Affairs gave $3.7 million for the work. The team is about 18 months into a 26-month project, said Jim Colvin, director of research and development at WillowWood.

So far, there have been 20 participants.

WillowWood, which was founded in 1907, has long worked to improve prosthetics but has largely relied on intuition, experience and feedback from test patients.

This study offers the staff an opportunity to work with medical experts to better understand the science behind what makes an artificial leg more responsive, more reliable and less likely to cause trouble for the remainder of the natural limb, Colvin said.

At Ohio State, study participants go through a series of exams to see how the amputee’s leg responds to the pressure and fit of the prosthetic’s socket.

“The prosthesis has a potential of hurting your limb,” said Ohio State researcher Dr. Chandan Sen.

When the amputees visit Ohio State, researchers perform exams and record information generated by sensors fitted into the prosthesis. This helps Sen and his team better understand how the prosthesis interacts with flesh and bone.

“Veterans are in their 20s, early 30s. They will live their whole lives (on a prosthesis),” Sen said. “They have to be able to enjoy life — they want to run, they want to play tennis.

”An ideal prosthesis is custom-fit to be snug enough to respond but doesn’t create undue pressure when it’s not in use, such as when a person is seated, said Sen, who directs the university’s wound center.

Finding that balance has been a challenge with above-the-knee amputees, Colvin said. For below-the-knee amputees, the company sells a system that uses a vacuum — something that didn’t work well above the knee until this study, he said.

Without a good fit, “it’s like a pair of shoes that is too loose.

”Jeff Denune, clinical director of prosthetics at WillowWood, said this study is putting science behind the belief that vacuum systems make for a better fit.

That includes information about oxygen levels in the limb, circulation and skin mechanics, Denune said.

It’s also allowed the team at WillowWood to come up with a better prosthesis for above-knee amputees, including a new liner that limits perspiration and a responsive vacuum that increases suction when a person is active and decreases it when they are seated.

The sensors send data to a computer, providing feedback for Denune so he can make adjustments.

A typical below-the-knee model costs about $12,000 to $15,000.

The company has yet to price an above-the-knee system, Colvin said. Johnson said he has less perspiration, no skin irritation and no rash with the experimental model.“There’s nothing I can’t do,” he said.


 All Sides with Ann Fisher Chandan Sen interview picture graphic.jpg

Wellness Wed

nesday: Allergies, Obamacare, Test Tube Organs

March 19, 2014 — 11:00 am

Mike Thompson interviews Chandan K. Sen, PhD, Director of The Ohio State University, Center for Regenerative Medicine and Cell Based Therapies. Topics span tissue engineering and cell based therapies work occurring at OSU and how regenerative medicine will change the shape of medicine in the future.

The interview begins at the 34:20 mark of the March 19, 2014 Wellness Wednesday Program.


Growing our cures cell by cell in the lab

Regenerative medicine centers are opening nationwide

November 18, 2013

This is the kind of thing that makes Chandan Sen hit a conference room table with excitement: Imagine that a soldier loses a hand in battle and is fitted with a prosthesis, said the director of the Center for Regenerative Medicine and Cell-Based Therapies at Ohio State University’s Wexner Medical Center.
In some cases, the soldier can use the prosthetic hand to grip a glass. But he can’t feel — he can’t tell if the glass is hot or cold, or how tightly to hold on.
But what if doctors could reprogram some of the soldier’s cells to grow nerve cells? Then those new nerve cells could work with the prosthesis and join the body’s existing nerve cells.
The soldier could grip and feel
“This is a realistic dream,” Sen said. “It’s not fiction anymore.”
To prove his point, he walked to a nearby lab where a mouse had been fitted with a small reflective patch on its belly.
Daniel Gallego, a nanotechnology researcher, squirted a DNA solution on the patch. That solution and the patch tell cells on the mouse’s skin to become nerve cells.
That same process could one day allow amputees to regain feeling.
“I’m 47 now,” Sen said. “By the time I retire, I want to see these products on the market.”


In the past decade, the top medical-research institutions in the United States have begun opening centers for regenerative medicine — the science of growing cells, tissue and organs to replace or repair damaged ones. Much of that is possible with stem cells, which can grow into many different kinds of tissue.


The National Center for Regenerative Medicine at Case Western Reserve University in Cleveland lists 53 programs nationwide doing research in the field. The largest are at the University of Pittsburgh and the University of California-Davis. Others, including Harvard, Stanford, Yale and Duke, have strong programs, too.
There are more than 4,500 ongoing clinical trials involving regenerative medicine, said Gregory A. Bonfiglio, with California-based Proteus Venture Partners, which invests in the field. They range from tissue engineering, such as growing organs, to training specific cells to fight cancer.


“It’s a fundamental change in the way you treat disease,” he said. “We’re going to cure (cancer).”


Ohio State opened its center in 2012 after consultation with Case Western’s, Sen said. The centers try to complement each other’s work without duplicating.


Ohio State’s advantage is that it has so many kinds of expertise in one place, Sen said. He said regenerative medicine needs input from different fields to advance. For example, engineers can help build the scaffolding for tissue to grow on, and dentists can advise on how a partially regrown jaw could work in a patient. 


Seven schools in the university are involved with the center: medicine, engineering, pharmacy, dentistry, arts and sciences (with its chemists and physicists), nursing and veterinary medicine. More than 200 faculty members are involved in the research.


Funding comes from the university, outside industry that could sell the products being developed, and the state and federal governments. The U.S. military and related agencies, such as the Department of Veterans Affairs, have pumped hundreds of millions of dollars into the field to develop treatments for wounded service members.
Dr. David Dean, an associate professor of plastic surgery at Ohio State, is using a grant from the Armed Forces Institute of Regenerative Medicine to grow bone to repair cranial damage.
Dean said he wants to use 3-D printers to create a scaffold for stem cells to grow on. When the bone is finished growing in the lab, it can be implanted directly into patients’ heads. The scaffold would disappear, leaving just bone, he said.


“We’ve put lots of cranial implants in patients (in the past), but not ones that are reabsorbed,” he said.
Dr. Gail E. Besner, chief of pediatric surgery at Nationwide Children’s Hospital and a professor at Ohio State, is growing sections of small intestine to be used in children and adults who have life-threatening bowel conditions.
Beyond the ready availability of the intestines, patients who have the transplants won’t have to worry that their bodies could reject them, because the intestines will have been grown from their own cells.


“It’s revolutionary,” Besner said of regenerative medicine. 


That’s the kind of word that people in the field often use. In the history of tissue replacement, almost all of the advances have come in trying to move living tissue from one place to another, said Dr. Michael Miller, the chairman of the department of plastic surgery at Wexner Medical Center. 


Miller describes himself as an “end-user” of regenerative medicine. For the first time, doctors are seeing advancements in how they can manipulate tissue — growing it for a specific purpose, fitting it exactly where it should go.


He uses another of those words: “This is transformative.”


To ease shortage of organs, grow them in a lab?
June 21, 2013 

By the time 10-year-old Sarah Murnaghan finally got a lung transplant last week, she’d been waiting for months, and her parents had sued to give her a better shot at surgery.

Her cystic fibrosis was threatening her life, and her case spurred a debate on how to allocate donor organs. Lungs and other organs for transplant are scarce.

But what if there were another way? What if you could grow a custom-made organ in a lab?

It sounds incredible. But just a three-hour drive from the Philadelphia hospital where Sarah got her transplant, another little girl is benefiting from just that sort of technology. Two years ago, Angela Irizarry of Lewisburg, Pa., needed a crucial blood vessel. Researchers built her one in a laboratory, using cells from her own bone marrow. Today the 5-year-old sings, dances and dreams of becoming a firefighter — and a doctor.

Growing lungs and other organs for transplant is still in the future, but scientists are working toward that goal. In North Carolina, a 3-D printer builds prototype kidneys. In several labs, scientists study how to build on the internal scaffolding of hearts, lungs, livers and kidneys of people and pigs to make custom-made implants.

Here’s the dream scenario: A patient donates cells, either from a biopsy or maybe just a blood draw. A lab uses them, or cells made from them, to seed onto a scaffold that’s shaped like the organ he needs. Then, says Dr. Harald Ott of Massachusetts General Hospital, “we can regenerate an organ that will not be rejected (and can be) grown on demand and transplanted surgically, similar to a donor organ.”

That won’t happen anytime soon for solid organs like lungs or livers. But as Angela Irizarry’s case shows, simpler body parts are already being put into patients as researchers explore the possibilities of the field.

Just a few weeks ago, a girl in Peoria, Ill., got an experimental windpipe that used a synthetic scaffold covered in stem cells from her own bone marrow. More than a dozen patients have had similar operations.

Dozens of people are thriving with experimental bladders made from their own cells, as are more than a dozen who have urethras made from their own bladder tissue. A Swedish girl who got a vein made with her marrow cells to bypass a liver vein blockage in 2011 is still doing well, her surgeon says.

In some cases the idea has even become standard practice. Surgeons can use a patient’s own cells, processed in a lab, to repair cartilage in the knee. Burn victims are treated with lab-grown skin.

In 2011, it was Angela Irizarry’s turn to wade into the field of tissue engineering.

Angela was born in 2007 with a heart that had only one functional pumping chamber, a potentially lethal condition that leaves the body short of oxygen. Standard treatment involves a series of operations, the last of which implants a blood vessel near the heart to connect a vein to an artery, which effectively rearranges the organ’s plumbing.

Yale University surgeons told Angela’s parents they could try to create that conduit with bone marrow cells. It had already worked for a series of patients in Japan, but Angela would be the first participant in an American study.

“There was a risk,” recalled Angela’s mother, Claudia Irizarry. But she and her husband liked the idea that the implant would grow along with Angela, so that it wouldn’t have to be replaced later.

So, over 12 hours one day, doctors took bone marrow from Angela and extracted certain cells, seeded them onto a 5-inch-long biodegradable tube, incubated them for two hours, and then implanted the graft into Angela to grow into a blood vessel.

It’s been almost two years and Angela is doing well, her mother says. Before the surgery she couldn’t run or play without getting tired and turning blue from lack of oxygen, she said. Now, “ she is able to have a normal play day.”

This seed-and-scaffold approach to creating a body part is not as simple as seeding a lawn. In fact, the researchers in charge of Angela’s study had been putting the lab-made blood vessels into people for nearly a decade in Japan before they realized that they were completely wrong in their understanding of what was happening inside the body.

“We’d always assumed we were making blood vessels from the cells we were seeding onto the graft,” said Dr. Christopher Breuer, now at Nationwide Children’s Hospital in Columbus, Ohio. But then studies in mice showed that in fact, the building blocks were cells that migrated in from other blood vessels. The seeded cells actually died off quickly. “We in essence found out we had done the right thing for the wrong reasons,” Breuer said.

Other kinds of implants have also shown that the seeded cells can act as beacons that summon cells from the recipient’s body, said William Wagner, director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. Sometimes that works out fine, but other times it can lead to scarring or inflammation instead, he said. Controlling what happens when an engineered implant interacts with the body is a key challenge, he said.

So far, the lab-grown parts implanted in people have involved fairly simple structures — basically sheets, tubes and hollow containers, notes Anthony Atala of Wake Forest University whose lab also has made scaffolds for noses and ears. Solid internal organs like livers, hearts and kidneys are far more complex to make.

His pioneering lab at Wake Forest is using a 3-D printer to make miniature prototype kidneys, some as small as a half dollar, and other structures for research. Instead of depositing ink, the printer puts down a gel-like biodegradable scaffold plus a mixture of cells to build a kidney layer by layer. Atala expects it will take many years before printed organs find their way into patients.

Another organ-building strategy used by Atala and maybe half a dozen other labs starts with an organ, washes its cells off the inert scaffolding that holds cells together, and then plants that scaffolding with new cells.

“It’s almost like taking an apartment building, moving everybody out … and then really trying to repopulate that apartment building with different cells,” says Dr. John LaMattina of the University of Maryland School of Medicine. He’s using the approach to build livers. It’s the repopulating part that’s the most challenging, he adds.

One goal of that process is humanizing pig organs for transplant, by replacing their cells with human ones.

“I believe the future is … a pig matrix covered with your own cells,” says Doris Taylor of the Texas Heart Institute in Houston. She reported creating a rudimentary beating rat heart in 2008 with the cell-replacement technique and is now applying it to a variety of organs.

Ott’s lab and the Yale lab of Laura Niklason have used the cell-replacement process to make rat lungs that worked temporarily in those rodents. Now they’re thinking bigger, working with pig and human lung scaffolds in the lab. A human lung scaffold, Niklason notes, feels like a handful of Jell-O.

Cell replacement has also worked for kidneys. Ott recently reported that lab-made kidneys in rats didn’t perform as well as regular kidneys. But, he said, just a “good enough organ” could get somebody off dialysis. He has just started testing the approach with transplants in pigs.

Ott is also working to grow human cells on human and pig heart scaffolds for study in the laboratory.

There are plenty of challenges with this organ-building approach. One is getting the right cells to build the organ. Cells from the patient’s own organ might not be available or usable. So Niklason and others are exploring genetic reprogramming so that, say, blood or skin cells could be turned into appropriate cells for organ-growing.

Others look to stem cells from bone marrow or body fat that could be nudged into becoming the right kinds of cells for particular organs. In the near term, organs might instead be built with donor cells stored in a lab, and the organ recipient would still need anti-rejection drugs.

How long until doctors start testing solid organs in people? Ott hopes to see human studies on some lab-grown organ in five to 10 years. Wagner calls that very optimistic and thinks 15 to 20 years is more realistic. Niklason also forecasts two decades for the first human study of a lung that will work long-term.

But LaMattina figures five to 10 years might be about right for human studies of his specialty, the liver.

“I’m an optimist,” he adds. “You have to be an optimist in this job.”


Michael Rubinkam in Lewisburg, Pa., and Allen Breed in Winston-Salem, N.C., contributed to this story.
Hyperspectral Imaging: Shedding New Light on Wound Healing
September 12
, 2012

Imaging OSU Ron Xu.pngDa
vid Allen takes readings using a NIST standard reflectance diffuser prior to scanning a wound area on an anesthetized pig. Illumination comes from the broadband lights on the hyperspectral camera.Clinicians who treat severe wounds may soon have powerful new diagnostic tools in the form of hyperspectral imaging (HSI) devices, calibrated to new NIST standard reference spectra, which will provide unprecedented perspective on the physiology of tissue injury and healing.

For example, a key factor in wound healing is the amount of oxygen in the tissue – a function of the gradual re-establishment of small blood vessels severed in the injury. At present, that process can’t be assessed without biopsies or transcutaneous techniques limited to a single point.

 Many physicians would prefer to use completely non-invasive HSI methods that have become available in the past decade to measure perfusion and other variables that determine outcomes over large areas.

“The potential of HSI is there, its utility has been demonstrated, and people are aware of it,” says David Allen of PML’s Sensor Science Division. “But HSI isn’t being used routinely in the clinic yet. Why? One big reason is that standards aren’t in place. Individual researchers doing their own experiments show positive results. But when you start comparing an instrument in one lab to an instrument in another, the data are typically inconsistent.” Factors limiting repeatable results include biological variability (variations in skin pigmentation, tissue density, lipid content, and blood volume changes), and sensor variability related to calibration and best practices in the measurement protocol.  While the biological variability is beyond researchers’ control, the sensor variability can be minimized.

In pursuit of that goal, Allen and colleagues have now produced the first prototype “digital tissue phantoms” derived from bench-top simulations and in-vivo wound imaging. Phantoms are objects that are deemed reasonably equivalent proxies for the body or its components. The new PML digital tissue phantoms (DTPs) are a set of specific spectral signatures and images that correspond to different states of hemoglobin oxygenation due to ischemia (inadequate blood flow) which ultimately result in cell death due to oxygen deprivation.

Ultimately, more extensive and clinically validated versions of the phantoms can be used to calibrate spectral imaging devices of various kinds. Those devices will be able to detect the telltale spectral evidence of ischemia, revascularization, assorted pathologies, and other conditions suggestive of tissue viability at a wound site, on a microvascular scale – even during surgery.

But in order for that to happen, there must be a well-characterized and clinically validated correspondence between particular spectral signature and particular tissue conditions. Allen and scientists from Ron Xu’s group at the Ohio State University (OSU) Biomedical Engineering Dept, recently took a major step in that direction by imaging carefully manipulated ischemic wounds in an anesthetized pig. “This is the first time anybody has looked at a porcine skin flap animal model hyperspectrally,” Allen says. “The collection of the hyperspectral data for use as a reference is a small but very significant
On two areas of the animal’s back, flaps of skin were raised, silicone-plastic sheets were placed beneath the skin to inhibit reperfusion, and the incisions were closed. On adjacent areas were a skin flap without plastic sheets and an untreated control area. Allen scanned all the areas with a highly sensitive hyperspectral imager, using illumination from a standard broadband light source.  In this work, a typical scan encompassed 240 different wavelengths, spaced about 2 nm apart, ranging from 400 nm to 880 nm. As a reflectance reference, each image also included light from a NIST-traceable standard diffuser. Readings at each wavelength were then stacked into “data cubes” for each scanned position.

A hyperspectral line camera with four broadband light sources acquires images with the lens at center. A typical scan captures images at hundreds of discrete wavelengths that differ by as little as 2 nanometers.
Imaging OSU Ron Xu 2.png
“We really nailed it,” Allen says. “We found that we can reproduce the tissue spectrum – including the oxygenation level of hemoglobin – to within one standard deviation, well within the natural variability of
the tissue.”
The work is the latest development in an initiative that began about five years ago at the behest of former NIST Director William Jeffrey. “He met some people in the field, biomedical engineers and researchers who had begun doing this kind of work, and asked how NIST could help,” Allen says. “This community was excited to partner with NIST in working towards advancing this technology.”

Soon thereafter, Allen’s group applied for, and received, competitive NIST funding to develop standards for the nascent field. The principle investigators included are Toni Litorja, Jeeseong Hwang, Antonio Possolo, Eric Shirley and David Allen.  One part of that award supported use of a PML device called the hyperspectral image projector (HIP), developed by Joe Rice and others at NIST, which reproduces complex spectral-spatial images very accurately by precision control of digital micromirror devices. (See Figure 3.)
When medically significant hyperspectral scenes are projected, they are referred to as digital tissue phantoms.  They allow realistic medical scenes to be produced repeatedly without the variability and expense that would occur if the medical procedure was repeated every time that a hyperspectral image was evaluated. Already Allen’s group has been able to generate HIP-projectable spectral signatures that correspond to different levels of oxygenation
in tissue.

Currently, accumulating the data for DTPs is a time-consuming process: Each scan takes from tens of seconds to a minute or more. “That’s the state of the technology right now,” Allen says. “But in the future, we’ll have ‘snapshot’ hyperspectral scans for real-time imaging, including video. Eventually, we want to get to the point at which you can see the blood perfusing through the tissue.”

As more measurements accumulate, Allen says “we’ll be able to collect a standard set of these data cubes that are well known and well characterized, and make them available as a kind of library with an indefinite shelf life. Users could then come here with their instruments, view our projections, and see if they get the same results. We have done the same sort of thing in the past, providing ‘ground truth’ data for satellite sensors that measure ocean color.” Because the spectra are in digital form, they can be reproduced indefinitely and identically.

So far, Allen’s group has had productive collaborations with OSU and at the University of Texas (UT) at Southwestern Medical Center, where scientists continue to make HSI measurements of various surgical procedures. More will join the effort. “We need to repeat the procedure in different labs using different approaches,” Allen says, using both in-vivo sources and bench-top apparatus that can be tuned to simulate the reflectance signature of different organs at different oxygenation levels. In the long run, these studies will make it possible for HSI to be used as a non-invasive diagnostic tool that will provide rapid results with a much greater ability to discriminate between healthy and diseased tissue.  Some examples include burns, chronic wounds, and tissue margins for surgical removal of tumors.  Establishing the measurement uncertainties will help guide researchers in determining the relationship between the optical measurements and what is clinically significant.

And there are other, quite different, potential uses as well. In addition to optical medical imaging, Allen is also investigating HSI’s potential in areas including environmental and defense applications such as diseases of coral reefs and the detection of hidden explosive devices. Results to date are highly promising.
 A hyperspectral image such as this one, which integrates scans from 240 different wavelengths, can be used as a digital tissue phantom. The "datacube" for this image of a 15 cm X 5 cm ischemic wound combines readings from 740 individual lines and about 600 rows at 12 bits per pixel.
Imaging OSU Ron Xu 3.png
Current Discoveries
July 30, 2012

New Recruits
Dr. Jianjie Ma joins Regenerative Medicine faculty

Jianjie Ma, P



Ma comes to Ohio State from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey (UMDNJ) where he is a university-named professor and acting chair of the Department of Physiology and Biophysics, as well as Chief of the Division of Developmental Medicine and Research. During his time at UMDNJ, Dr. Ma founded the Graduate Program in Physiology and Integrative Biology, which is jointly sponsored by UMDNJ and Rutgers University. He served on the Scientific Advisory Board for the Cancer Institute of New Jersey. In addition, he served on several National Institutes of Health study sections and various editorial boards.

In addition to his faculty appointment with UMDNJ, Dr. Ma also founded his own company, TRIM-edicine Inc., a university spinoff biotechnology company. TRIM-edicine develops novel biopharmaceutical products for the treatment of several important unmet medical needs. One specific therapeutic protein is MG53, which targets diseases involved chronic and acute tissue damage. The other drug is ATAP, which targets apoptosis for cancer treatment.

Dr. Ma is an NIH-funded researcher, prominently and widely published on the topics of muscle physiology, aging, cardiovascular disease, cystic fibrosis, apoptosis and cancer biology. He has authored more than 130 publications and holds 10 patents. He has assembled an international team of collaborators working on translational research. His group maintains close collaboration with pharmaceutical industries for joint development efforts toward translating basic discovery into clinical application.

Dr. Ma received his bachelor’s degree in Physics from Wuhan University in China, and came to the United States through the CUSPEA (China-US Physics Examination Application) program after his undergraduate education. He was chosen to represent the Department of Physiology and Biophysics at the Graduate Student Symposium of Baylor College of Medicine, where he received his PhD in 1989. Dr. Ma went on to become an Instructor of Physiology at Rush Medical College (1989-1991) where he received postdoctoral fellowship and research grants from the Muscular Dystrophy Association, and a University Committee on Research Grant Award. Dr. Ma joined the Department of Physiology and Biophysics at Case Western Reserve University in 1992, and became a tenured Associate Professor in 1997. In 2001, he was recruited to UMDNJ as a university-named professor.

Dr. Ma has trained numerous graduate and postgraduate students, and many of them have become leaders in academia, industry, medicine and law firms. He was an established investigator for the American Heart Association (AHA) and served as advisor for many AHA postdoctoral and scientist development fellows. He is an outstanding mentor and educator, and has coordinated the teaching of both medical and graduate students at Case Western Reserve University as well as the Robert Wood Johnson Medical School. He is also actively involved in teaching and collaboration with the Chinese Academy of Sciences and universities in China.
In the News
June 26, 2012: Surgeons Perform World’s First Two Bioartificial Stem-cell Based Laryngotracheal Transplantations Using Nanofiber Solutions Scaffolds
Collaboration between Nanofiber Solutions and the Karolinska Institutet produces first synthetic laryngotracheal implants seeded with the patient’s stem cells to be successfully transplanted into human patients in Russia.  
COLUMBUS, Ohio – Nanofiber Solutions, LLC, an Ohio-based developer, manufacturer and marketer of 3-D synthetic scaffolds to advance basic research, tissue engineering and regenerative medicine announced today the first and second successful transplants of its tissue engineered laryngotracheal implants seeded with cells from the patients’ bone marrow.
The surgeries were performed June 19th and 21st at the Krasnodar Regional Hospital (Russia) by Dr. Paolo Macchiarini, Professor of Regenerative Surgery at the Karolinska Institutet (Stockholm, Sweden), and colleagues.  Dr. Macchiarini led an international team that included Dr. Vladimir Porhanov, head of Oncological and Thoracic Surgery at Kuban State Medical University (Russia), Dr. Jed Johnson, Nanofiber Solution’s Chief Technology Officer who created the synthetic organs, Harvard Bioscience (Boston, USA) who produced the bioreactor, and Dr. Alessandra Bianco at University of Rome, Tor Vergata, who performed mechanical testing during scaffold development.
Both patients, a 33 year-old mother from St. Petersburg and a 28 year-old man from Rostov-on-Don, were in auto accidents and suffered from a narrowing of the laryngotracheal junction for which they already had failed previous surgeries. Transplantation was the last option for the patients to have normal quality of life. Immediately following transplantation, both patients were able to speak and breathe normally.
Nanofiber Solutions, lead by Dr. Johnson, designed and built the nanofiber laryngotracheal scaffolds specifically to match the dimensions of each patient’s natural larynx and trachea, while Harvard Bioscience provided a bioreactor used to seed the scaffold with the patients’ own stem cells.  Although this procedure represents the world’s first and second successful use of synthetic laryngotracheal implants, it is Nanofiber Solution’s second and third successful organ implants using their synthetic scaffolds within the last year.
Nanofiber Solutions’ scaffolds mimic the body’s physical structure and allow for a more successful seeding, growth and differentiation of stem cells.  Because the cells used to regenerate the larynx and trachea were the patients’ own, doctors report there has been no rejection of the transplants and the patients are not taking immunosuppressive drugs.  These are the first patients entering a clinical trial on regenerative medicine replacement, which is supported by a Megagrant of the Government of the Russian Federation, designed to invite leading worldwide scientists to Russian universities.
"We are proud to work side-by-side with Dr. Macchiarini and his team as they help define this new world of stem cell seeded synthetic transplants.” said Ross Kayuha, Nanofiber Solutions CEO. 
“Tissue engineering and regenerative medicine are exciting fields that hold much promise for effective medical solutions,” continued Kayuha. “Our nanofiber scaffolds provide an innovative and ideal platform to create an array of new clinical solutions.  In the hands of pioneering surgeons like Dr. Macchiarini the possibilities are almost limitless.  We wish the patients continued success as they recover and hope they enjoy long, happy lives with their families.”
These historic accomplishments continue a major breakthrough in medicine, namely the ability to produce synthetic nanofiber-based organs.  These surgeries are also at the forefront of two major trends in medicine today.  The first is tissue engineering, or the use of artificial scaffolds in the body, and the second is regenerative medicine, including the use of a patient’s own stem cells to increase the likelihood of a scaffold’s acceptance and success. 
About Nanofiber Solutions, LLC (www.nanofibersolutions.com)
Based on a technology licensed through The Ohio State University, Nanofiber Solutions is a global developer, manufacturer and marketer of 3-D products to advance life science research, tissue engineering and regenerative medicine.  The company develops nanofiber-based scaffolds used in products ranging from cell culture plates for lab research to bioartificial implants for clinical use.  Nanofiber Solutions sells our cell culture products worldwide through our website and distribution partners; including Sigma-Aldrich (worldwide), Neuromics (US), Akron Biotech (US), and Cambridge BioScience (UK).  Nanofiber Solutions is located in the TechColumbus center in Columbus, OH.


Surgeons to complete key heart research at Nationwide Children’s Hospital

tissue-engineers-art-ggchl4f5-10607gfx-tissue-engineers-heart-eps Christopher Breuer.jpg 

8, 2012
It’s already quite incredible when surgeons reroute blood flow in a baby’s malf
ormed heart.
Now imagine them doing it by growing a new vessel from the baby’s own cells.
Two Yale researchers who pioneered a method of engineering human tissue to repair potentially deadly congenital heart defects have agreed to come to Columbus to continue their work at Nationwide Children’s Hospital.
Drs. Christopher Breuer and Toshiharu Shinoka are planning to start in September with a team of eight people, Breuer said. They’re currently one patient into a six-patient study using the engineered vessel in children with heart defects. They’ll complete the study in Columbus.
Surgeons now typically use a synthetic graft to reroute blood flow in the hearts of babies with ventricle problems.
The hope — and research in Japan holds promise — is that the children will fare better with vessels built from their own bodies, said Breuer, who has been working with Shinoka for more than a decade. The two will be co-directors of Children’s new tissue-engineering program.
The research team and Children’s officials say they see this study as a starting point. They say they envision a day when cells from patients’ bodies can be manipulated in a variety of ways to fix myriad problems in the heart and other organs.
“Really, this is epic, transformational,” said Dr. Mark Galantowicz, chief of cardiothoracic surgery and co-director of the hospital’s heart center.
When he’s reconstructing hearts, he’s often left with synthetic materials that don’t grow with a child’s body and sometimes need to be replaced with additional surgeries, Galantowicz said.
The experimental graft made from the patient’s tissue “is replacing something that’s missing and has the potential to grow with the
“Already (Shinoka) and I are talking about 10 different potential applications within the world of children’s heart surgery.”
Synthetic grafts are susceptible to problems including clotting, infection and rejection.
The new science works like this: The researchers put cells from the patient’s bone marrow on a biodegradable scaffold in the shape of a tube, then put the scaffold in an incubator for a couple of hours. After running tests, they implant it in the child.
In six months, the scaffolding has disappeared and the vessel resembles an artery or a vein, Breuer said.
“It really is amazing. It’s kind of a miracle,” he said. “Really, what tissue engineering is, at least ours, is much more like regenerative medicine.”
Breuer, who is a pediatric surgeon, said he’s excited about Children’s new hospital and research facilities.The creation of the vessels requires special laboratories, several of which are available here, and Children’s already has an exceptional congenital heart program with lots of patients who would be a good fit for the research, Breuer said.
Children’s would not share the doctors’ salaries. Shinoka was not available for an interview yesterday.
Dr. R. Lawrence Moss, surgeon-in-chief at Children’s, came from Yale and said he was eager to recruit the team.
“As surgeons who take care of kids with congenital anomalies, a huge, huge problem for us is not having tissue to create the things they’re born without,” he said.
The current study “is preliminary work and even the human clinical trial only scratches the surface of the potential of this work.”
CRMCBT Announcement
June 8, 2012: Preeminent Tissue Engineering Team to Establish Program at Nationwide Children's Hospital. Experts to also work with OSU’s new Regenerative Medicine and Cell Based Therapies Program

Christopher Breuer profile pic.pngChristopher Breuer, MD, Toshiharu Shinoka, MD, PhD, and their tissue engineering team will be joining the faculty of Nationwide Children’s Hospital and The Ohio State University College of Medicine this fall.  Breuer and Shinoka, currently at Yale University, were the first in the world to tissue engineer blood vessels and implant them in human infants for repair of congenital heart defects. They currently have US Food and Drug Administration (FDA) approval to conduct the first U.S human trial to investigate the safety and effectiveness of this method. They and their team will conduct this work at Nationwide Children’s Hospital.

“The fundamental problem faced by surgeons caring for children with congenital anomalies (defects that are present at birth) is the lack of sufficient tissue for reconstruction that is capable of growth,” said Mark Galantowicz, MD, FACS, Chief of Cardiothoracic Surgery and Co-Director of The Heart Center at Nationwide Children’s Hospital, as well Associate Professor of Surgery at The Ohio State University College of Medicine. “Tissue engineering is the process by which the child’s own cells are used to ‘grow’ new tissue or organs for repair of these birth defects and it holds the incredibly exciting potential to completely change how we care for our patients.” 

Dr. Breuer and Dr. Shinoka will serve as Co-Directors of the new Tissue Engineering Program at Nationwide Children’s. Dr. Breuer will also serve as the Director for Tissue Engineering in The Ohio State University Wexner Medical Center’s new Center for Regenerative Medicine and Cell Based Therapies.

“The careers of Dr. Breuer and Dr. Shinoka exemplify what can be accomplished by highly focused surgeons with unwavering dedication to solving a problem faced by pediatric patients,” said R. Lawrence Moss, MD, Surgeon-in-Chief at Nationwide Children's Hospital and the E. Thomas Boles Jr., Professor of Surgery at The Ohio State University College of Medicine.

Following medical school at Dartmouth and training in Surgery and Pediatric Surgery at Brown University, Dr. Breuer served as the Chief of Pediatric Surgery for the United States Air Force. He then joined Yale University where he is currently Director of Tissue Engineering and Associate Professor of Surgery and of Pediatrics. At Yale, Dr. Breuer assembled a spectacular team and began to fulfill his longstanding dream of building blood vessels for children with heart defects.  He obtained National Institutes of Health (NIH) funding upon first submission and currently holds three major NIH grants, a grant from the American Heart Association, and extensive industry funding. He has received numerous honors recognizing his contributions, including the Jacobsen Promising Investigator Award from the American College of Surgeons which is given to the most innovative young surgical investigator in the country.

Dr. Shinoka received his medical degree at Hiroshima University and his PhD in biomedical engineering at Tokyo Women’s Medical University. He was a leading clinical congenital heart surgeon at the Heart Institute of Japan before joining Yale University, where he has been Director of Pediatric Cardiovascular Surgery and Associate Professor of Surgery and of Pediatrics for the last five years. Dr. Shinoka is a successful surgeon-scientist, conducting nearly two decades of increasingly sophisticated tissue engineering research, both bench-top and translational. As an accomplished clinical congenital heart surgeon, Dr. Shinoka will join the Heart Center surgical team at Nationwide Children’s and will also be involved in the Heart Center’s Research initiatives that resonate well with his foundation in congenital heart disease translational research.

“We are delighted at the prospect of working with Dr. Breuer in our new Center for Regenerative Medicine and Cell Based Therapies,” said Steven Gabbe, MD, Senior Vice President for Health Sciences and CEO of the Wexner Medical Center at The Ohio State University. “The goal of our Center is to work with partners such as Nationwide Children’s and Battelle to discover novel treatments, and Dr. Breuer’s work is certainly indicative of the kind of research and clinical care we want to foster.”
May 18, 2012: Columbus Business First 
Heal Thyself: Tissue on Dem
Nanofiber Solutions LLC in the TechColumbus incubator is set to start production in July of lab dishes and microscope slides laced with custom-made ultra-thin fibers that researchers say work better than formless gel for growing cells. The company has created artificial objects that can be implanted in the human body where cells can populate and grow blood vessels around the object in incorporate as part of the human body. The company is working with Ohio State's Center for Regenerative Medicine and Cell-Based Therapies to bring tissue-replacement surgery to Wexner Medical Center. Dr. Chandan Sen is quoted. More...
May 15, 2012: CoE 2012 "Building Bridges" Excellence Award to Prof. Chandan K Sen
College of Engineering 2012 Building Bridges Excellence Award to Prof. Chandan K Sen.jpgThe “Building Bridges” Excellence Award for the College of Engineering was established in 2007 and consists of $1,500 along with an award. The award is presented each year to a non-COE faculty member at Ohio State University whose collaborative work with the College of Engineering has advanced the excellence, impact and reputation of both colleges and the University. The award will be presented at annual College of Engineering Faculty Awards Banquet.
The award will be made to an individual faculty member outside of the College of Engineering for demonstrated excellence and accomplishment in the development and implementation of collaborative activities and programs between their academic unit and the College of Engineering. Consideration will be given to how this collaboration advances excellence and impact in education, research, and/or outreach and engagement of both organizations.
College of Engineering Faculty and staff may make nominations. Please limit your nomination to two pages or less and provide supporting materials that are brief and concise, yet with sufficient information to permit a rational selection. The nominating letter should address the following:
•Describe the primary activity and accomplishment that supports consideration for the “Building Bridges”
Excellence Award.
•Explain how this activity and accomplishment promotes the achievement of excellence and impact in the College of Engineering and other organizations within the University.
Nominations should also include a citation of no more than 50 words, highlighting the reasons for the nomination; this citation will be used in the program if the nominee is selected for this award.
Selection Committee
The College Awards Committee will evaluate applicants and make a recommendation to the Dean of the College of Engineering, who will select one or more award recipients each year.
April 19, 2012: The Wall Street Journal, MarketWatch.com
April 16, 2012: Columbus Business First